In the BJCYH cohort, IHC assays demonstrated that the levels of CD8+ T cells were decreased while FOXP3+ T cells were increased in cancer tissues in comparing with matched normal tissues (Figure 2B, Figure 2—figure supplement 1D). The gene discussed is FOXP3; the disease is cancer.